DNA Repair Pathways in Breast Cancer: from Mechanisms to Clinical Applications

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2023 Jun 8

PMID 37289340

Authors

Muhammad Tufail

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is a complex disease with various subtypes and genetic alterations that impact DNA repair pathways. Understanding these pathways is essential for developing effective treatments and improving patient outcomes.

Area Covered: This study investigates the significance of DNA repair pathways in breast cancer, specifically focusing on various pathways such as nucleotide excision repair, base excision repair, mismatch repair, homologous recombination repair, non-homologous end joining, fanconi anemia pathway, translesion synthesis, direct repair, and DNA damage tolerance. The study also examines the role of these pathways in breast cancer resistance and explores their potential as targets for cancer treatment.

Conclusion: Recent advances in targeted therapies have shown promise in exploiting DNA repair pathways for BC treatment. However, much research is needed to improve the efficacy of these therapies and identify new targets. Additionally, personalized treatments that target specific DNA repair pathways based on tumor subtype or genetic profile are being developed. Advances in genomics and imaging technologies can potentially improve patient stratification and identify biomarkers of treatment response. However, many challenges remain, including toxicity, resistance, and the need for more personalized treatments. Continued research and development in this field could significantly improve BC treatment.

Citing Articles

Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.

Rai S, Du W, Zhang J, Yu H, Deng Y, Fei P Front Med (Lausanne). 2024; 11:1462810.

PMID: 39421870 PMC: 11483370. DOI: 10.3389/fmed.2024.1462810.

DNA damage response in breast cancer and its significant role in guiding novel precise therapies.

Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H Biomark Res. 2024; 12(1):111.

PMID: 39334297 PMC: 11437670. DOI: 10.1186/s40364-024-00653-2.

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.

Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer.

Magadeeva S, Qian X, Korff N, Florkemeier I, Hedemann N, Rogmans C Int J Mol Sci. 2023; 24(24).

PMID: 38139296 PMC: 10743768. DOI: 10.3390/ijms242417467.

References

Wang J, Lei K, Han F . Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 2018; 22(12):3855-3864. DOI: 10.26355/eurrev_201806_15270. View

Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S . Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells. Life (Basel). 2022; 12(6). PMC: 9224881. DOI: 10.3390/life12060811. View

Engle K, Kumar G . Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur J Med Chem. 2022; 239:114542. DOI: 10.1016/j.ejmech.2022.114542. View

Otto T, Sicinski P . Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017; 17(2):93-115. PMC: 5345933. DOI: 10.1038/nrc.2016.138. View

Bai J, Li Y, Zhang G . Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2018; 14(4):348-362. PMC: 5785171. DOI: 10.20892/j.issn.2095-3941.2017.0033. View

Shahin R, Aljamal S . Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies. Future Sci OA. 2022; 8(3):FSO778. PMC: 8890118. DOI: 10.2144/fsoa-2021-0116. View

Kamranvar S, Rani B, Johansson S . Cell Cycle Regulation by Integrin-Mediated Adhesion. Cells. 2022; 11(16). PMC: 9406542. DOI: 10.3390/cells11162521. View

Matthews H, Bertoli C, de Bruin R . Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2021; 23(1):74-88. DOI: 10.1038/s41580-021-00404-3. View

Bontenbal M, Sieuwerts A, Klijn J, Peters H, Krijnen H, Sonneveld P . Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br J Cancer. 1989; 60(5):688-92. PMC: 2247289. DOI: 10.1038/bjc.1989.341. View

10.

Bontenbal M, Sieuwerts A, Peters H, Sonneveld P, Foekens J, Klijn J . Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells. J Steroid Biochem Mol Biol. 1990; 37(6):1097-101. DOI: 10.1016/0960-0760(90)90472-w. View

11.

Van Dierendonck J, Wijsman J, Keijzer R, van de Velde C, Cornelisse C . Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol. 1991; 138(5):1165-72. PMC: 1886031. View

12.

Tufail M, Wu C . RANK pathway in cancer: underlying resistance and therapeutic approaches. J Chemother. 2022; 35(5):369-382. DOI: 10.1080/1120009X.2022.2129752. View

13.

Yuan M, Zhao Y, Arkenau H, Lao T, Chu L, Xu Q . Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct Target Ther. 2022; 7(1):187. PMC: 9200817. DOI: 10.1038/s41392-022-01013-y. View

14.

Sheehan B, Neeb A, Buroni L, Paschalis A, Riisnaes R, Gurel B . Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clin Cancer Res. 2022; 28(14):3104-3115. PMC: 9365343. DOI: 10.1158/1078-0432.CCR-21-4531. View

15.

Cheung-Ong K, Giaever G, Nislow C . DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013; 20(5):648-59. DOI: 10.1016/j.chembiol.2013.04.007. View

16.

Liu H, Liu Y, Yang F, Zhang L, Zhang F, Hu X . Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020; 48(7):3638-3656. PMC: 7144926. DOI: 10.1093/nar/gkaa130. View

17.

Jager M, Blokzijl F, Kuijk E, Bertl J, Vougioukalaki M, Janssen R . Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Res. 2019; 29(7):1067-1077. PMC: 6633256. DOI: 10.1101/gr.246223.118. View

18.

Lans H, Marteijn J, Vermeulen W . ATP-dependent chromatin remodeling in the DNA-damage response. Epigenetics Chromatin. 2012; 5:4. PMC: 3275488. DOI: 10.1186/1756-8935-5-4. View

19.

He B, Xu T, Pan Y, Wang H, Cho W, Lin K . Nucleotide excision repair pathway gene polymorphisms are linked to breast cancer risk in a Chinese population. Oncotarget. 2016; 7(51):84872-84882. PMC: 5356705. DOI: 10.18632/oncotarget.12744. View

20.

Budden T, Bowden N . The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis. Int J Mol Sci. 2013; 14(1):1132-51. PMC: 3565312. DOI: 10.3390/ijms14011132. View